2. Indian Biotechnology Sector
§ The Biotechnology industry in ₰ In Asia Pacific market, India
India to reach $11.6 billion by occupies 28.66% market share.
2017-Global Industry Analysis. ₰ India is in 12th rank in the
§ The opportunities for investors in world in biotechnology and
Biotech industry are manifold. 3rd largest in Asia-Pacific after
§ In 2010-11 the Indian Biotech Japan and Korea.
industry registered 21.5% growth, ₰ The Sector employees
touching $4 billion mark clocking approximately 20,000
Rs 18,399.34 Cr. scientists and over 352
§ The Biopharma segment continues companies drive it towards
to dominate biotech industry with further growth.
61.77% share in the overall ₰ Karnataka is the Biotech
revenue. Capital of India
3. Karnataka-India’s Biotech Hub
₴ The Biotech capital of India. • Extensive Intellectual Capital
₴ 60% of biotech companies are – Sector focused SEZs-Mysore,
having base in Bangalore. Mangalore, Hubli-Dharward,
₴ 50% of the total revenues in Belgaum, Shimoga,
national biotechnology sector. Gulbarga,Kolar & Mandya.
₴ Growth in industrial output of – 86 acre Bitochnology park-
Karnataka’s biotech companies “Bangalore Helix” with 52 acre
CAGR 11% per annum. Alexandria Knowledge Park in
₴ Extensive Intellectual Capital Bangalore.
– 12 Biotechnology finishing • Pro Industry policy-State Millennium
schools under millennium Biotech Policy II 2010, State
biotech policy II Industrial Policy 2009-14
– 103 R&D Centers – K-Bio Venture capital fund of
US$ 10.4 million with 26% stake
holding by GoK
4. Divisions
The Indian Biotechnology sector can be
divided into the segments of
biopharmaceuticals, bioservices,
bioagriculture, bioindustrial and
bioinformatics.
Nearly 40 percent of the biotech companies
operate in the biopharma sector, followed by
the bioservices (21 percent), bioagri (19
percent), bioinformatics (14 percent) and
lastly the bioindustrial sector (5 percent).
5. Biopharmaceuticals Bioservices
• This constitutes the largest • The Bioservices market is
segment of the Indian biotech the second largest sector of
industry both in terms of the Indian Biotechnology
domestic and export revenues.
Industry.
• About 70 percent of the domestic
biotech industry comprises of the • The market’s growth can be
Biopharma sector. attributed to the fact that
• Of the total 325biotechnology India has become a popular
companies in India, more than 40 destination for clinical trial,
percent are in the biopharma contract research and
sector. manufacturing activities.
• Vaccines, therapeutics and
diagnostics fall into this
category.
6. Agricultural Bioinformatics / BioIT
Biotechnology
• This segment can be segmented • This sector deals with the
into Hybrid seeds and transgenic creation and maintenance of
crops, Biopesticides and extensive electronic databases
Biofertilizers. on various biological systems
and is probably the smallest
part of the current domestic
• Genetically modified cotton or biotechnology industry.
commonly known as Bt cotton • However, India is known for
constitute approximately 77 its strong IT base and it is due
percent of the revenue of this to this that India is sure to
sector whereas Biopesticides and become a leading destination
Biofertilizers together account for work in the bioinformatics
only for 23 percent of the arena.
revenues by agricultural
biotechnology.
7. Bioindustrial
• This industry predominantly consists
of enzyme manufacturing and
marketing companies.
• These enzymes are used in industries
such as detergents, textiles, food,
leather, paper and pharmaceuticals.
This generates 6 percent of the
revenues of the biotechnology industry.
8. List of Top Biotech 20 Companies
Serum Institute of India
Biocon
Panacea Biotec
Rasi Seeds
Nuziveedu Seeds
Novo Nordisk India
Venkateshwara Hatcheries
Indian Immunologicals
Mahyco Monsanto Biotech
GlaxoSmithKline Pharma
Aventis Pharma
Shantha Biotechnics
Eli Lilly and Company(India)
Mahyco Seeds
Bharat Serums and Vaccines
Novozymes South Asia
Invert India
Bharat Biotech International
Ankur Seeds
Advanced Enzyme Technologies
9. Serum Institute of Biocon Panacea Biotec
India
Vaccine King Collective Expertise Product Innovation
With a record sales of Rs 950.95 Biocon's integrated business
crore in 2010-11, approach coupled with its Panacea Biotec has added new drugs to
collective expertise has its product basket like Siropan,
Serum Institute of India continues to enabled it to establish a
be a leader in the vaccines Lower A, Myelogen Forte, Inrica,
significant presence in the TOFF Expectorant, Toff DC,
market. global
Business: Manufacturing and Upright SP and Trepro.
biopharmaceutical market. Business: Manufacturer of
marketing of vaccines
Business: Biopharmaceuticals pharmaceuticals and
and immuno-biologicals and industrial enzymes biopharmaceuticals
CEO: Dr C S Poonawalla (CMD) CEO: Kiran Mazumdar Shaw CEO: Soshil Kumar Jain (MD)
Biotech Revenue: Rs 950.95 crore Biotech Revenue: Rs 823 crore Biotech Revenue: Rs 600 crore
Start-up Year: 1966 Start-up Year: 1978 Start-up Year: 1984
Address: 212/2, Hadapsar, Off Soli Address: 20th KM Hosur Road, Address: B-1 Extn/G-3, Mohan Co-
Poonawalla Road, Electronic City, Bangalore – operative Industrial Estate, Mathura
Pune- 411 028 560100 Road, New Delhi – 110 044
10. Nuziveedu Seeds Rasi Seeds Novo Nordisk India
Bt Cotton Maker Transgene Developer Insulin Leader
Novo Nordisk India enjoys a lion's
Rasi Seeds accounted for 35 Nuziveedu Seeds is working on share in the Indian insulin
percent of the total Bt its own indigenous transgene market.
cotton seeds sold in India to combat bollworms and
in the year 2011. these technologies are
Business: Producing and expected to be Novo Nordisk India
marketing commercialized soon. CEO: Melvin Oscar D'Souza (MD)
agri-biotechnology products Business: Manufacturer of hybrid Biotech Revenue: Rs 222 crore
CEO: M Ramasami (MD) cotton seeds
Business: Diabetes care products,
Biotech Revenue: Rs 333.33 CEO: M Prabhakar Rao human growth hormone and
crore Biotech Revenue: Rs 226.42 crore
haemostasis management.
Start-up Year: 1973 Start-up Year: 1973
Start-up Year: 1990
Address: 273, Kamarajanar Address: 7C, Surya Towers, 105
Road, Attur, Salem - 636 SP Road, Secunderabad – Address: 8th Floor, Raheja Towers,
102, Tamil Nadu 500 003 East Wing, 26/27, MG Road,
Bangalore- 560 001
11. Venkateshwara Indian Mahyco Monsanto
Hatcheries Immunologicals Biotech
Poultry Passion Animal Health Specialist The Technologist
Mahyco Monsanto Biotech (India), a
Venkateshwara Hatcheries Indian Immunologicals Ltd (IIL) 50:50 joint venture with Mahyco
dominates the Indian poultry has bagged the distinction of and Monsanto Holdings Pvt Ltd
vaccines market being the largest exporter of (MHPL), was created to bring the
with a share of over 60 percent. veterinary biological in Asia. benefits of Bollgard cotton
Venkateshwara Hatcheries Indian Immunologicals Ltd (IIL) technology to farmers in India.
Business: Engaged in R&D, Business: Manufacturer of animal Mahyco Monsanto Biotech (India)
production and export of and human biological Business: Marketing of Bt technology
vaccines and diagnostics kits CEO: KV Balasubramaniam in India
CEO: Anuradha Desai Biotech Revenue: Rs 157.90 crore CEO: Dr MK Sharma (MD)
(Chairperson) Start-up Year: 1983 Biotech Revenue: Rs 150.30 crore
Biotech Revenue: Rs 190.50 crore Address: Road No.44, Jubilee Start-up Year: 1998
Start-up Year: 1971 Hills, Hyderabad - 500 033 Address: Ahura Centre, 5th Floor, 96,
Address: Venkateshwara House, SN Mahakali Caves Road, Andheri
114/A/2, (East),
Pune - Sinhgad Road,Pune - 411030 Mumbai - 400 093
12. GlaxoSmithKline Shantha
Pharma Aventis Pharma Biotechnics
Novel Concepts Anti-rabies Vaccine Leader The Trend Setter
With growing competition from the
local low-priced products, GSK As the first Indian company to launch
has initiated novel concepts to an r-DNA vaccine in 1997,
bring awareness on the use of Aventis Pharma leads the anti-rabies Shantha heralded a new beginning
vaccines in the country. vaccine market in India, having for biotechnology in India.
GlaxoSmithkline Pharmaceuticals a market share of 60 percent. Shantha Biotechnics
Business: Engaged in the sale of Aventis Pharma Business: Research, development,
Business: Marketing of manufacture and marketing of
vaccines
biotechnology products biotechnology-based human health
CEO: Dr Hasit B Joshipura (MD) care products
Biotech Revenue: Rs 120 crore CEO: Dr Shailesh Ayyangar (MD)
CEO: KI Varaprasad Reddy
Start-up Year: 2001 Biotech Revenue: Rs 119.65 crore
Biotech Revenue: Rs 115 crore
Address: GSK House, Dr Annie Address: Aventis House, 54/A, Sir Start-up Year: 1993
Besant Road, Worli, Mumbai - Mathuradas Vasanji Road,
400030 Andheri (East), Mumbai - 400 Address: Serene Chambers, 3rd Floor,
093 Banjara Hills, Road No. 7,
Hyderabad - 500 034
13. Eli Lilly and Bharat Serums and
Company(India) Mahyco Seeds Vaccines
TB Fighter Bt Cotton Pioneer Recombinant Therapeutics
Player
Bharat Serums and Vaccines has
Established in 1964, Mahyco is a been focusing on developing
pioneer and leader in the Indian new generation recombinant
Eli Lilly India has committed $50 therapeutics that replace the
million to fight Multi-Drug seed industry.
traditional plasma products
Resistant Tuberculosis (MDR- Maharashtra Hybrid Seed Company
TB). Ltd Bharat Serums and Vaccines
Eli Lilly & Company (India) Business: Diagnostics solutions for Business: Manufacturing and
GM crop testing marketing of biological
Business: Marketing of products
pharmaceutical products CEO: BR Barwale (Chairman)
CEO: Bharat Daftary (CMD)
CEO: Sandeep Gupta (MD) Biotech Revenue: Rs 110.69 crore
Biotech Revenue: Rs 108.49 crore
Biotech Revenue: Rs 112 crore Start-up Year: 1964
Start-up Year: 1971
Start-up Year: 1993 Address: PO Box 76, Jalna -
Aurangabad Road, Dawalwadi, Address: 16th Floor, Hoechst
Address: Plot No. 92, Sector 32, House, Nariman Point, Mumbai
Institutional Area, Gurgaon - Dist.- Jalna,
- 400 021
122 001 Maharashtra – 431203
14. Novozymes South Bharat Biotech
Asia Invert India International
Enzymatic Endeavors The Veterinarian Healthcare Specialist
Intervet India is one of the largest
MNCs in India dedicated to
animal health. It offers a range
of products consisting of
biological, therapeutics and
productive hormones.
Bharat Biotech was established in 1996
Novozymes produces and sells more Intervet India with the objective of
than 600 enzyme products in manufacturing unique vaccines
130 different countries, the Business: R&D and manufacturing
and biotherapeutics.
largest geographical markets of veterinary biological
Bharat Biotech International
being Europe, North America CEO: Dr Lino Componovo (MD)
and Asia. Business: Manufacturer of human
Biotech Revenue: Rs 80.58 crore vaccines and biopharmaceuticals
Novozymes South Asia CEO: Dr Krishna M Ella
Business: Industrial enzymes Start-up Year: 1997
Biotech Revenue: Rs 70.27 crore
CEO: GS Krishnan Address: Intervet House, 33, Pune- Start-up Year: 1996
Biotech Revenue: Rs 100 crore Nagar Road, (Behind Eden New initiatives: Manufacture of human
Start-up Year: 2000 Gardens), Pune - 411 014 rabies vaccines, formulation of
Address: #16, 7th Floor, Innovator, various vaccines and
International Technology Park, biopharmaceuticals. Address:
Road No. 65 Jubilee Hills,
Whitefield Road, Bangalore - Hyderabad
560 066
15. Advanced Enzyme
Ankur Seeds Technologies
Agribiotech Player The Catalyst
Advanced Enzyme Technologies
Ankur Seeds boasts of having produces enzymes and probiotics
over 115 hybrids in various worth over $20 million annually
crops. It also has a large and it is the largest manufacturer
collection of proprietary of serratiopeptidase.
germplasm with novel traits Advanced Enzyme Technologies
of all crops. Business: R&D, manufacturing and
Ankur Seeds marketing of enzymes for
Business: Engaged in research, different industries
processing and developing CEO: Chandrakant L Rathi (MD)
hybrid and Bt seeds Biotech Revenue: Rs 69.30 crore
CEO: MG Shembekar (MD) Start-up Year: 1958
Biotech Revenue: Rs 69.50 crore Address: 5th Floor 'A' Wing Sun
Start-up Year: 1976 Magnetica, Galaxy Accolade,
Address: 27, New Cotton Market Next to LIC Building, Service
Layout, Nagpur - 440 018 Road, Louis Wadi, Near Teen
Hath Naka,Thane-(w)400604
16. Market Forecast Favorable Climate
• According to the “India in • Indian Copyright Act, 1957
Business”, Ministry of External • The Patent Act, 1970
Affairs, Govt of India the forecast • Indian Patents and Design Act,
for 2015 is that the Indian biotech 1972
industry would have an annual • The Trademarks Act, 1999
revenues in excess of US$13
billion • Biotechnology Patent Facilitating
Cell (BPFC)
• According to Global Industry
Analysis-The Biotechnology • Foundation of Biotechnology
industry in India to reach $11.6 Awareness and Education (FBAE)
billion by 2017 • National Research Development
Corporation (NRDC)
